In Figure 4 in his review article (1), Schleußner shows a smooth muscle cell in the uterus and signal transduction mechanisms. Unfortunately, there are numerous errors in the accompanying text.
The β-adrenergic receptor in the uterus is the β2-adrenoceptor. This matters because the pharmacological agents used are β2-adrenoceptor agonists (, page 433).
There are different G proteins. The G protein involved in the signal transduction of the β2-adrenoceptor is the stimulatory Gs protein (, page 320).
The represented oxytocin receptors and prostaglandin receptors also act through G proteins—in particular, Gq proteins. Also, for these receptors, phospholipase C as an effector is missing. There is not only one prostaglandin receptor, but it needs to be specified that prostaglandin F2α induces a contraction of the smooth muscle cells through the FP-receptor (, page 445).
The receptors are represented by different symbols. The prostaglandin receptor suggests a channel-like structure with one pore and two receptor units. This is erroneous. Prostaglandin receptors are not among the group of the ligand-controlled ion channels but among the group of G-protein-linked receptors. All depicted receptors should have been represented with 7 transmembrane domains (, page 64–66).
There is no molecule with the name “inosidol phosphate.” The molecule that mobilizes Ca2+ from intracellular stores is called inosidol-1,4,5-trisphosphate and originates from the breakdown of phosphatidylinositol-4,5-bisphosphate through phospholipase C (, page 64–66).
The soluble guanylyl cyclase as a receptor for NO-pharmacological agents is lacking from the figure. Guanylyl cyclase synthesizes cGMP from GTP. Guanylyl cyclase should have been included in the figure because cAMP-synthesizing adenylyl cyclase is also shown (, page 535).
Calcium channel antagonists of the dihydropyridine type, such as nifedipine, inhibit the Ca2+ influx through voltage-dependent calcium channels located in the plasma membrane, not the release of calcium from intracellular stores (, page 505).
Indomethacine is obsolete because of its high rate of adverse side effects and should be replaced with substances that are better tolerated , such as ibuprofen (, page 211–12).
Prof. Dr. med. Roland Seifert
Institut für Pharmakologie
Medizinische Hochschule Hannover
Conflict of interest statement
The author declares that no conflict of interest exists.
|1.||Schleußner E: The prevention, diagnosis and treatment of premature labor. Dtsch Arztebl Int 2013; 110(13): 227–36. VOLLTEXT|
|2.||Mutschler E, Geisslinger G, Kroemer HK, Menzel S, Ruth P (eds.): Mutschler Arzneimittelwirkungen: Pharmakologie, Klinische Pharmakologie, Toxikologie. 10th edition. Stuttgart: Wissenschaftliche Verlagsgesellschaft 2013.|